Keith Bridwell M.D.,
relishes the challenges of spinal surgery
|
Keith Bridwell M.D., relishes the challenges of spinal surgery |
|
|
|
|
|
|
||||||
|
|
|||||||||||||||||||||||||||||
|
 |
|
Bladder cancer returns sooner with each recurrence By Darrell Ward
The study also identified two proteins in tumor cells that may help predict the risk of a first or second recurrence. The findings were published online Sept. 5 in the journal Cancer and in the Sept. 15 print edition. "Our findings may help improve the guidelines doctors use for follow-up care for superficial bladder cancer," said lead author Yan Yan, M.D., Ph.D., assistant professor of surgery. "They also could lead to a better understanding of why these tumors recur." Doctors will diagnose some 56,500 new cases of bladder cancer this year, according to the American Cancer Society. It is the fourth-most-common cancer in men and the ninth-most-common in women. About 80 percent of those cases are superficial bladder cancer, which is cancer that has not yet invaded the deeper layers of the bladder wall. The disease recurs in more than half of those patients and has a fatality rate of 20 percent. "Little is known about the biology of multiple sequential recurrent tumors or about which patients are most at risk for sequential recurrence," said Yan, who also is a member of the Cancer Prevention and Control Program at the Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and the medical school. The study involved 270 patients with superficial bladder cancer who were treated between January 1994 and April 1999; follow-up time ranged from one to 54 months. Of these patients, 47 percent had one or more recurrences, 14 percent had two or more recurrences and 5 percent had three or more recurrences. The researchers found that the average time from initial treatment to first recurrence was 23 months, while the time to second and third recurrence averaged 15 and 13 months, respectively. The investigators also tested each patient's tumor tissue for several tumor markers, proteins that often are associated with cancer. Patients whose original tumor tested positive for the marker Ki-67 had a 49 percent higher risk for a first recurrence than did patients whose tumors lacked the marker. Tumors that recurred and tested positive for the p53 protein were at 173 percent greater risk for an additional recurrence. The researchers found no statistically significant link between p53 and the risk of a first recurrence. "The finding that Ki-67 is important for the first recurrence and p53 is important for a second recurrence came as a surprise," Yan said. "It raises questions that might lead to a better understanding of the mechanics of recurrence." The study also confirmed that a tumor's stage and grade remain the most important factors in determining a patient's prognosis and probability of recurrence. Tumor stage refers to the degree to which a tumor has penetrated the organ; tumor grade classifies a tumor according to its microscopic appearance. Yan now plans to examine the timing of follow-up visits for patients with superficial bladder cancer. In light of the current findings, doctors may need to see some patients more often to adjust for the progressively faster recurrence pattern. But the procedures needed to spot a recurrence are inconvenient and sometimes painful. "Would patients prefer fewer uncomfortable exams but later tumor detection, or more exams and earlier detection?" Yan asked. "Patients must decide for themselves, but we can provide them with information and help as they make the decision." |
|
||||||||||||||||||||||||||
|
|
